BSX

SEC source: 0001225208-23-000048 · doc4.xml · nonDerivative · entry 1

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,262

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022.

F2 · balance_after: Includes shares acquired on June 30, 2022 under the Boston Scientific Employee Stock Purchase Plan (formerly Boston Scientific Global Employee Stock Purchase Plan) based upon the most current data available.

SEC source: 0001225208-23-000047 · doc4.xml · derivative · entry 3

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,134 shares

Expires 2022-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F1 · shares: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022.

F1 · derivative.exercise_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022.

F1 · derivative.expiration_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022.

SEC source: 0001225208-23-000047 · doc4.xml · nonDerivative · entry 2

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 273,382

SEC source: 0001225208-23-000047 · doc4.xml · nonDerivative · entry 1

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 277,424

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022.

SEC source: 0001225208-22-012852 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,413

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $46.49 to $46.75 inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-22-012777 · doc4.xml · derivative · entry 6

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 79,264 shares

Expires 2023-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.

SEC source: 0001225208-22-012777 · doc4.xml · nonDerivative · entry 3

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,871

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-22-012777 · doc4.xml · nonDerivative · entry 2

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 296,135

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-22-012606 · doc4.xml · nonDerivative · entry 1

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,479

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-22-012558 · doc4.xml · derivative · entry 3

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 29,599 shares

Expires 2024-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.

SEC source: 0001225208-22-012558 · doc4.xml · nonDerivative · entry 2

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,559

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $45.97 to $46.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-22-012558 · doc4.xml · nonDerivative · entry 1

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,591

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-22-012296 · doc4.xml · derivative · entry 5

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 649

Underlying: Common Stock · 649 shares

Expires 2023-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 3, 2019, the first anniversary of the date of grant.

F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 3, 2019, the first anniversary of the date of grant.

SEC source: 0001225208-22-012296 · doc4.xml · nonDerivative · entry 4

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,992

SEC source: 0001225208-22-012296 · doc4.xml · nonDerivative · entry 3

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,288

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-22-011987 · doc4.xml · nonDerivative · entry 1

Connors Nelda J · CIK 0001478748 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 27,246

F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.47 to $44.485, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-22-011792 · doc4.xml · nonDerivative · entry 1

Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,533.99

F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.701 to $42.755 inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-22-011694 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,913

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-22-011453 · doc4.xml · derivative · entry 5

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 82,567 shares

Expires 2023-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.

SEC source: 0001225208-22-011453 · doc4.xml · derivative · entry 4

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 173,041

Underlying: Common Stock · 43,260 shares

Expires 2024-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.

SEC source: 0001225208-22-011453 · doc4.xml · nonDerivative · entry 3

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,767,665

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $41.79 to $42.20, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-22-011453 · doc4.xml · nonDerivative · entry 2

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,893,492

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-22-011453 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,850,232

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-22-012296 · doc4.xml · nonDerivative · entry 2

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,639

F1 · balance_after: Includes shares acquired on June 30, 2022 under the Boston Scientific Employee Stock Purchase Plan (formerly Boston Scientific Global Employee Stock Purchase Plan) based upon the most current data available.

SEC source: 0001225208-22-011013 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,591

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $40.315 to $40.745 inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-22-010699 · doc4.xml · derivative · entry 5

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,567

Underlying: Common Stock · 82,567 shares

Expires 2023-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.

SEC source: 0001225208-22-010699 · doc4.xml · derivative · entry 4

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,301

Underlying: Common Stock · 43,260 shares

Expires 2024-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.

SEC source: 0001225208-22-010699 · doc4.xml · nonDerivative · entry 3

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,767,665

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $38.94 to $39.84, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-22-010699 · doc4.xml · nonDerivative · entry 2

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,893,492

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-22-010699 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,850,232

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-22-010698 · doc4.xml · derivative · entry 3

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,394 shares

Expires 2022-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 2, 2018, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 2, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-22-010698 · doc4.xml · nonDerivative · entry 2

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,002

SEC source: 0001225208-22-010698 · doc4.xml · nonDerivative · entry 1

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,999

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-22-010382 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,913

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.133 to $42.28 inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-22-010120 · doc4.xml · derivative · entry 6

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,134

Underlying: Common Stock · 82,567 shares

Expires 2023-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.

SEC source: 0001225208-22-010120 · doc4.xml · derivative · entry 5

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 259,561

Underlying: Common Stock · 43,261 shares

Expires 2024-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.

SEC source: 0001225208-22-010120 · doc4.xml · nonDerivative · entry 4

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,767,665

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $40.23 to $40.69, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-22-010120 · doc4.xml · nonDerivative · entry 3

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,893,493

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-22-010120 · doc4.xml · nonDerivative · entry 2

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,850,232

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-22-010120 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,767,665

F1 · kind: This transaction involved a gift of securities by the reporting person to the Michael F. Mahoney 2 Year Qualified Annuity Trust - 2022, which is administered by an independent trustee.

SEC source: 0001225208-22-009534 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,413

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $41.93 to $42.17, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-22-009395 · doc4.xml · derivative · entry 5

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,701

Underlying: Common Stock · 82,567 shares

Expires 2023-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.

SEC source: 0001225208-22-009395 · doc4.xml · derivative · entry 4

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 302,822

Underlying: Common Stock · 43,261 shares

Expires 2024-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.

SEC source: 0001225208-22-009395 · doc4.xml · nonDerivative · entry 3

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,133,122

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $40.72 to $41.23, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-22-009395 · doc4.xml · nonDerivative · entry 2

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,258,950

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-22-009395 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,215,689

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-22-009191 · doc4.xml · derivative · entry 3

Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,270

Underlying: Common Stock · 1,089 shares

Expires 2025-08-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on August 2, 2022, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on August 2, 2022, the first anniversary of the date of grant.

SEC source: 0001225208-22-009191 · doc4.xml · nonDerivative · entry 2

Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,602

SEC source: 0001225208-22-009191 · doc4.xml · nonDerivative · entry 1

Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,922

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-22-009274 · doc4.xml · nonDerivative · entry 1

Connors Nelda J · CIK 0001478748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,877

F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $41.575 to $41.595, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F2 · balance_after: The most recently filed Form 4 reported 15,965 shares directly beneficially owned by the reporting person and 50,442 shares held by the Nelda J. Connors Trust, for which the reporting person is the sole trustee. 4,990 of the shares previously reported as being directly beneficially owned were in fact held indirectly, by the Nelda J. Connors Trust. A subsequent share transfer of 9,990 shares from the Nelda J. Connors Trust to the reporting person to be held directly was initiated to facilitate the sales reported on this Form 4.